Wart Removal: Freezing, Burning, and Laser Options

Cutaneous warts caused by human papillomavirus (HPV) are among the most common dermatologic conditions encountered in clinical practice, affecting approximately 10% of the general population and up to 20% of school-age children. Despite the availability of numerous treatment modalities, no single approach achieves universal clearance, and recurrence remains a clinical challenge due to HPV latency in surrounding tissue. Office-based wart removal centers on three primary modalities—cryotherapy with liquid nitrogen, electrodesiccation and curettage (ED&C), and laser therapy—each with distinct mechanisms, efficacy data, patient selection criteria, and procedural requirements. Choosing among these modalities requires assessment of wart subtype, anatomic location, patient age, pain tolerance, and prior treatment history.

Clinical Overview

Cutaneous warts are caused by a diverse group of HPV genotypes: HPV 1, 2, and 4 are responsible for the majority of common warts (verruca vulgaris), plantar warts (verruca plantaris), and flat warts (verruca plana). Periungual warts, filiform warts, and mosaic plantar warts represent clinically distinct subtypes with implications for treatment selection. Warts are confined to the epidermis and superficial dermis—the infected keratinocytes serve as the viral reservoir, and effective treatment requires destruction or immunological clearance of HPV-infected tissue to the level of the dermal-epidermal junction or beyond.

Three mechanisms of action underlie office-based wart removal: (1) cryonecrosis via rapid freeze-thaw injury to cells (cryotherapy); (2) thermal coagulation and mechanical disruption through electrosurgical current (ED&C); and (3) selective photothermolysis or ablation targeting chromophores or water content of wart tissue (laser). All three modalities induce local tissue destruction with the intent of removing HPV-infected keratinocytes; emerging evidence suggests that treatment-induced inflammation may also stimulate an immunological bystander response that contributes to wart clearance and reduces recurrence.

Overall clearance rates for individual treatments range from 60% to 85% for a single treatment course, with recurrence rates of 20–40% within 1 year regardless of modality—reflecting HPV latency in clinically normal-appearing surrounding skin. Combination protocols (e.g., cryotherapy + topical salicylic acid, or cryotherapy + intralesional immunotherapy) achieve higher clearance rates than any single modality.

How It Works

Cryotherapy mechanism: Liquid nitrogen (∓96°C) applied to the wart surface produces rapid intracellular ice crystal formation, cell membrane disruption, and tissue necrosis. The freeze-thaw cycle creates an inflammatory response—histamine and prostaglandin release from damaged cells—that potentiates immune recognition of HPV-infected keratinocytes. A blister forms between the dermis and epidermis within 6–24 hours as the necrotic epidermis separates; the blister roof detaches over 7–14 days, and the treated area re-epithelializes over 2–4 weeks. The depth of cryonecrosis is proportional to freeze time: a 10-second freeze achieves approximately 2–3 mm depth; a 20-second freeze reaches 4–5 mm, sufficient to reach the dermal-epidermal junction in most plantar and palmar warts.

ED&C mechanism: Electrodesiccation uses a high-frequency, high-voltage, low-amperage alternating current (monoterminal) to desiccate and char tissue. Curettage with a sharp curette mechanically removes the desiccated necrotic material. The combined procedure destroys HPV-infected epidermal tissue while creating an inflammatory wound that heals by secondary intention, and the heat generated may penetrate to the papillary dermis to address deeper infection.

Laser mechanism: Three laser types are used for warts, each with a distinct mechanism: CO2 laser (10,600 nm) ablates water-containing tissue non-selectively; Nd:YAG laser (1,064 nm) targets oxyhemoglobin in wart vasculature; and pulsed dye laser (PDL; 585 or 595 nm) uses selective photothermolysis to destroy the dilated capillaries that supply wart tissue, inducing ischemic necrosis of the infected epidermis.

Ideal Candidates

Cryotherapy is the first-line office procedure for most common, plantar, periungual, and filiform warts in adults and older children (>10 years). It is particularly appropriate for:

• Multiple, clustered warts amenable to broad freezing
• Warts in pregnancy (preferred over laser or ED&C due to minimal systemic exposure)
• Warts overlying skin with normal pigmentation (risk of PIH higher in darker skin types; caution in Fitzpatrick IV–VI)
• Patients willing to tolerate moderate procedural pain without topical anesthesia

ED&C is preferred for:

• Solitary, well-defined, thick verruca vulgaris on the hands, fingers, or dorsal feet
• Filiform warts amenable to base curettage
• Warts that have failed repeated cryotherapy
• Cases where rapid definitive single-treatment clearance is prioritized over wound healing time
• Not recommended for plantar warts (high scar recurrence rate) or periungual warts (nail matrix damage risk)

Laser is preferred for:

• Recalcitrant warts failing multiple cryotherapy or ED&C courses
• Periungual and subungual warts where nail plate avoidance is required
• Mosaic plantar warts covering large surface areas
• Pediatric patients where pain of cryotherapy is poorly tolerated (laser under topical anesthesia is better accepted)
• Immunocompromised patients with treatment-resistant wart burden

Treatment Protocol

Cryotherapy protocol (liquid nitrogen):

1. Pre-treatment preparation: Pare down thick plantar or palmar warts with a #15 scalpel blade or pumice stone 24 hours before treatment to remove hyperkeratotic callus, reducing the insulating effect on freeze penetration. Topical anesthesia (EMLA 60 minutes pre-procedure under occlusion) recommended for plantar warts, periungual warts, and pediatric patients.
2. Liquid nitrogen application: Two delivery methods are used—cotton-tip applicator dip and cryogen spray gun. The cryospray device (e.g., CryoAlfa, Brymill Cry-Ac) with a 1–1.5 mm nozzle provides superior control and depth of freeze compared to cotton tip, particularly for plantar warts requiring 4–5 mm freeze depth.
3. Freeze-thaw cycle: Apply liquid nitrogen until a 2–3 mm ice ball extends beyond the wart margin (lateral halo). Freeze time varies by wart size and location: small hand warts (5–10 mm): single 10–15 second freeze; plantar warts (>10 mm): two 15–20 second freeze-thaw cycles (each cycle = freeze 15–20 seconds, thaw completely, repeat). Allow complete thaw between cycles—double freeze-thaw cycles improve efficacy by 40% over single freeze in controlled studies.
4. Post-treatment wound care: Advise patient that a blister will form within 6–24 hours. Instruct not to unroof the blister; allow it to resolve spontaneously. Apply petrolatum and non-adherent dressing. Blister fluid is infectious (contains HPV-infected keratinocytes)—gloves during home wound care should be advised. Re-epithelialization complete in 2–4 weeks.
5. Retreatment interval: Every 2–3 weeks until clearance or maximum 6 treatment sessions before escalating to alternative modality.

Cryotherapy efficacy: Published clearance rates range from 60–80% after 3–4 treatment sessions. A Cochrane systematic review (Kwok et al., 2012) of 19 randomized trials found no significant efficacy difference between cryotherapy and topical salicylic acid for common warts, but patient preference for professional cryotherapy was higher. Recurrence at 12 months: 20–30% of cleared cases.

Electrodesiccation and curettage (ED&C) protocol:

1. Local anesthesia: Inject 1% lidocaine with epinephrine 1:100,000 in a ring block or direct infiltration (0.5–1.0 mL) at the wart base. Epinephrine provides hemostasis and extends anesthesia duration. Wait 3–5 minutes for full vasoconstriction.
2. Electrodesiccation: Using a fine-tip electrode (Bovie monopolar unit, setting 20–30 per wart), apply current to the wart surface until tissue blanches and desiccates. For thick warts, initial light desiccation facilitates curettage; avoid excessive depth to prevent full-thickness dermal burn.
3. Curettage: Using a 3–4 mm sharp dermal curette, scrape the desiccated wart tissue with firm, circular strokes until the firmer, smooth, pink base (normal dermis) is reached. Curettage distinguishes wart tissue (soft, friable, grainy with thrombosed capillaries appearing as black dots) from normal dermis (smooth, firm, pink). Remove all friable tissue.
4. Second desiccation pass: After curettage, a second light desiccation of the wound base destroys any residual HPV-infected keratinocytes at the wound margin and provides hemostasis.
5. Wound care: Apply petrolatum and non-adherent dressing. Change twice daily. Wound heals by secondary intention in 2–4 weeks depending on size and location. Advise against heavy activity for 1–2 weeks for lower extremity wounds.

ED&C efficacy: Single-session clearance rates of 65–80% reported in case series for common hand and finger warts. Recurrence rate: 15–25% at 12 months. Scarring is an expected outcome—patients must be counseled that ED&C reliably produces a permanent scar at the treatment site, and it should not be used for plantar warts where scarring may cause chronic pain from pressure on scar tissue.

Laser treatment protocol:

Pulsed Dye Laser (PDL; 585 nm or 595 nm): The most widely published laser modality for warts. Targets oxyhemoglobin in the dilated capillary loops that supply wart vasculature. Selective photothermolysis produces endovascular coagulation, thrombosis of wart feeding vessels, and ischemic epidermal necrosis. PDL settings for warts: 7–10 J/cm² fluence, 0.45–0.5 ms pulse duration, 7 mm spot size; 2 passes per session; dynamic cooling device (DCD) spray 30–50 ms pre-pulse reduces epidermal thermal injury.

• Sessions every 3–4 weeks; 3–6 sessions typically required
• Clearance rate: 64–79% after 3–4 sessions (Gibbs et al., meta-analysis 2012)
• Minimal scarring; preferred for periungual, facial, and pediatric warts
• Limitation: less effective for thick hyperkeratotic plantar warts without pre-treatment paring

CO2 Laser (10,600 nm): Ablates all water-containing tissue non-selectively. Used for bulk ablation of mosaic plantar warts, large common warts, and recalcitrant warts unresponsive to PDL. Settings: continuous wave or superpulse mode, 5–20 W, 2 mm spot; ablation performed layer-by-layer until normal dermis reached. CO2 laser generates viral HPV DNA-containing plume—practitioners must use N95 or powered air-purifying respirator (PAPR), smoke evacuator, and appropriate plume filtration.

• Single-session clearance rate: 60–72% for recalcitrant plantar warts (Street et al., 2002)
• Wound healing: 3–4 weeks; pain post-procedure more significant than PDL
• Scarring risk: low with careful depth control
• Local anesthesia with ring block or tumescent infiltration required

Nd:YAG Laser (1,064 nm): Penetrates more deeply (4–6 mm) than PDL, making it suitable for thick plantar and periungual warts. Targets oxyhemoglobin with less selective photothermolysis than PDL, producing both vascular and thermal tissue destruction. Settings: 100–200 J/cm², 35 ms pulse duration, 5 mm spot; 1–2 passes. Post-treatment edema and discomfort more prominent than PDL. Sessions every 4–6 weeks; 3–5 sessions typical. Clearance rate: 60–75% for plantar and periungual warts in case series.

Expected Results & Timeline

All three modalities require multiple treatment sessions for maximal efficacy. Practitioners should counsel patients on realistic expectations at treatment initiation:

• Cryotherapy: 3–6 sessions every 2–3 weeks; first clinical response (wart thinning, surface change) at 2–4 weeks post-first treatment; complete clearance expected by 8–12 weeks in responsive cases
• ED&C: Single session; wound heals in 2–4 weeks; if residual wart tissue persists at 6-week follow-up, repeat treatment or modality change is indicated
• PDL: 3–6 sessions every 3–4 weeks; progressive vessel destruction and wart necrosis visible between sessions; full clearance assessed at 6-week post-final-session visit
• CO2 laser: Often single session with complete ablation; wound healing 3–4 weeks; recurrence assessment at 3-month follow-up

Post-clearance monitoring for 6–12 months is recommended to detect recurrence from HPV-positive surrounding skin. Recurrence risk is highest in immunocompromised patients, mosaic/plantar wart variants, and those with periungual warts where subungual HPV reservoirs are difficult to treat.

Risks & Side Effects

Risks vary by modality and anatomic site:

• Cryotherapy: Post-inflammatory hyperpigmentation or hypopigmentation (particularly Fitzpatrick III–VI); blistering beyond treatment site; tendon or nerve damage from excessive freeze depth in digit, wrist, or ankle locations; treatment failure (20–40%)
• ED&C: Scarring (universal—a planned outcome, but extent varies); infection (2–4%); bleeding (managed with silver nitrate or electrodesiccation); nail matrix damage if performed periungually without careful technique
• PDL: Purpura lasting 7–14 days (expected from vessel targeting); PIH in darker skin types (reduce fluence by 20–30% in Fitzpatrick IV–VI); blister formation; incomplete clearance requiring repeated sessions
• CO2 laser: Scarring (low with careful technique); prolonged wound healing (3–4 weeks); HPV plume hazard for operating team; PIH; pain requiring prescription analgesia post-procedure

Comparison with Alternatives

The three office-based modalities complement rather than replace topical and immunological treatments:

• vs. Topical salicylic acid (home therapy): Cochrane review found comparable efficacy to cryotherapy for common warts (complete clearance: 73% salicylic acid vs. 70% cryotherapy at 12 weeks), but patient compliance with daily home therapy is poor (40–60% adherence rates in practice). Office-based treatment is preferred for painful plantar warts, recalcitrant warts, and immunocompromised patients.
• vs. Intralesional immunotherapy (Candida antigen, bleomycin): Intralesional Candida antigen (0.3 mL per wart, 4-weekly injections) achieves clearance rates of 62–88% in recalcitrant warts and may induce systemic immunity clearing distant warts. Intralesional bleomycin (1 unit/mL, 0.1 mL per wart) achieves 60–80% clearance for plantar and periungual warts resistant to other treatments. These are complementary escalation strategies—often combined with cryotherapy.
• vs. Topical immunotherapy (imiquimod, 5-fluorouracil): Imiquimod 5% cream (applied 3×/week) achieves clearance in 40–68% of genital and common warts; 5-FU cream (applied daily) is used as adjunct therapy. These topical agents are often combined with office cryotherapy in alternating regimens.
• vs. Photodynamic therapy (PDT): ALA-PDT (aminolevulinic acid 20% + red light 630 nm) has shown efficacy for recalcitrant palmoplantar and periungual warts in small case series (clearance 56–73%), but is not widely available and requires specialized equipment.

When to Consult a Specialist

Referral or co-management is indicated when:

• Warts fail to clear after 6 sessions of cryotherapy and 2–3 alternative modality treatments—immunocompromised status evaluation and possible dermatology-immunology co-management is warranted
• Rapidly expanding wart burden in a previously controlled patient: consider HIV testing, hematologic malignancy evaluation, or review of immunosuppressive regimen
• Periungual warts requiring nail avulsion for adequate treatment access
• Warts in the oral or anogenital mucosa—ensure appropriate HPV typing, dysplasia screening, and gynecologic or urologic co-management as indicated
• Epidermodysplasia verruciformis (EDV) or other HPV-associated oncogenic risk states requiring surveillance
• Suspected squamous cell carcinoma arising within chronic wart (verrucous carcinoma)—any wart unresponsive to repeated treatment with atypical features should be biopsied

Frequently Asked Questions

Q: Which treatment modality has the highest single-session clearance rate?
A: CO2 laser ablation achieves the highest single-session clearance rate (60–72%) due to complete tissue ablation in one pass. However, it requires local anesthesia, has the longest wound healing time, and generates infectious HPV plume. For most first-line office treatment, cryotherapy or ED&C are preferred for common warts due to lower cost and equipment requirements.

Q: How many cryotherapy sessions are typically needed before escalating?
A: If no clinical response (wart thinning, surface change, partial clearance) is observed after 4–6 cryotherapy sessions spaced 2–3 weeks apart, the modality should be changed or combined with intralesional therapy (Candida antigen or bleomycin). Continuing cryotherapy beyond 6 sessions without clinical response is unlikely to produce clearance.

Q: Is ED&C appropriate for plantar warts?
A: Generally not. ED&C reliably produces a scar at the treatment site, and scarring on the plantar foot surface creates a firm fibrous nodule that can cause chronic pressure pain—sometimes worse than the original wart. Cryotherapy, PDL, or CO2 laser are preferred for plantar warts as they avoid the scar-related complications of ED&C in a weight-bearing location.

Q: What precautions are needed for laser wart treatment in terms of HPV plume?
A: CO2 and Nd:YAG laser ablation generates a plume containing viable HPV DNA. All practitioners and assistants in the room must wear N95 or higher respiratory protection; a high-efficiency smoke evacuator with ULPA filtration must be used within 2 cm of the treatment site; and appropriate eye protection (wavelength-specific laser goggles) for both patient and operator is mandatory. PDL plume risk is lower (no ablation) but smoke evacuation is still recommended.

Q: Does immunocompromised status affect which modality to choose?
A: Yes. Immunocompromised patients (transplant recipients, HIV, hematologic malignancy, biologic therapy) have higher wart burden, greater treatment resistance, and higher recurrence rates. In these patients, combination approaches (cryotherapy + topical salicylic acid, or laser + intralesional Candida antigen) achieve higher clearance than single modalities. Intralesional immunotherapy (Candida antigen, BCG) depends on intact cell-mediated immunity and is less effective in severe immunosuppression.

References